Cordis gets EU thumbs up to use Cypher Select in diabetics
Cordis, a Johnson & Johnson company, has reported that its Cypher Select Plus Sirolimus-eluting coronary stent has received CE marking within the EU for treatment of patients with diabetes.

The New Brunswick, N.J.-based company said that the expanded indication for the Cypher Select Plus stent is based on numerous clinical studies, both randomized clinical trials as well as non-randomized trials that have been presented at major medical meetings or appeared in international peer reviewed publications, supporting the safety and efficacy of the device in patients with diabetes.

Featuring an enhanced stent delivery system, the Cypher Select Plus stent features the CYPH2ONIC hydrophilic coating technology, a coating technology that is more lubricious than previous Cypher stent products, increasing a physician's ability to navigate coronary arteries, according to Cordis.